Viking Therapeutics, Inc. is a clinical-stage company with a primary focus on developing innovative therapies for metabolic and endocrine disorders. The company's leading candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for recovery from hip fracture surgery. In addition to this, Viking Therapeutics is also advancing its thyroid receptor beta (TRb) agonist platform, currently in Phase 2, for the treatment of various disorders such as hypercholesterolemia, fatty liver diseases including non-alcoholic steatohepatitis (NASH), as well as for rare diseases like glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy (X-ALD). With its establishment in 2012 and being in the Health Care industry, Viking Therapeutics recently received a significant $632.50MPost-IPO Equity investment on 28 February 2024. Despite not disclosing the specific investors, these funds undoubtedly position the company for further advancements in its clinical programs. For more information, please visit Viking Therapeutics website.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $632.50M | - | 28 Feb 2024 | |
| Post-IPO Equity | $250.00M | - | 29 Mar 2023 | |
| Post-IPO Equity | $140.90M | - | 12 Jun 2018 | |
| Post-IPO Equity | $14.80M | - | 06 Dec 2017 | |
| Post-IPO Equity | $12.50M | 1 |
|
25 Aug 2016 |
No recent news or press coverage available for Viking Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
